Parallel Health is a technology company.
Parallel Health has raised $750K across 1 funding round.
Parallel Health has raised $750K in total across 1 funding round.
Parallel Health is a biotech-driven skin health company that develops personalized precision skincare products using custom phage therapy to target harmful bacteria in the skin microbiome. It serves individuals with chronic skin conditions such as acne, eczema, rosacea, melasma, and hidradenitis suppurativa, as well as those seeking targeted anti-aging solutions. By combining whole genome sequencing, clinical expertise, and personalized prescriptions, Parallel Health aims to improve skin health outcomes through a unique 3-step protocol involving microbiome testing, 1:1 provider support, and custom phage serums. The company has demonstrated early growth momentum with $2.3 million in pre-seed funding and recognition from industry leaders like TechCrunch Disrupt and Fast Company[1][2][4].
Founded in 2020 by Natalise Kalea Robinson and Nathan Brown, Parallel Health originated from a project within a larger cosmetics company exploring phage therapy for chronic skin conditions. The founders identified the need for personalized phage cocktails tailored to individual microbiomes, which led them to spin out Parallel Health to focus on this biotech-intensive approach. Early traction included participation in prestigious accelerators such as Stanford StartX and Illumina Accelerator, as well as notable media coverage and awards for innovation in dermatology[1][2][3][4].
Parallel Health rides the rising trend of precision health and microbiome science, leveraging advances in genomic sequencing and phage therapy to address antibiotic resistance and chronic skin conditions. The timing is favorable due to increasing consumer demand for personalized, science-backed skincare and growing interest in microbiome-based therapies beyond cosmetics. By pioneering personalized phage treatments, Parallel Health influences the broader dermatology and biotech ecosystems, potentially expanding into therapeutic applications and setting new standards for skin health management[1][3].
Looking ahead, Parallel Health is poised to expand its product offerings and deepen its microbiome data insights, potentially licensing phage technology for broader therapeutic use. Trends shaping its journey include the growing acceptance of microbiome science in healthcare, advances in telemedicine, and the urgent need for alternatives to antibiotics. As the company scales, its influence may extend beyond skincare into clinical dermatology and precision medicine, reinforcing its mission to improve human healthspan through targeted, data-driven solutions[1][3][4]. This positions Parallel Health as a pioneering force at the intersection of biotech and personalized skin health.
Parallel Health has raised $750K in total across 1 funding round.
Parallel Health's investors include Illumina Accelerator.
Parallel Health has raised $750K across 1 funding round. Most recently, it raised $750K Seed in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $750K Seed | Illumina Accelerator |